Your trusted source for GLP-1 research, news, and patient insights.
10 posts in this category
Melanotan II is sold as a tanning shortcut. See the FDA's own safety language, the published case reports, and where the 2026 peptide review stands.
An FDA panel backed 6 of 7 peptides for the compounding list. See the votes, what each was proposed to treat, and what has to happen next.
An FDA panel meets July 23-24 to weigh whether 7 peptides can be compounded. See which peptides, what the FDA recommends, and what it means.
Some peptides are FDA-approved medicines and some "research" peptides are risky. A plain-language guide to telling safe sources from unsafe ones.
How to vet a peptide provider in 2026: licensed pharmacy, named clinician, honest labeling, plus free tools and red flags to know before you buy.
Lab testing finds many grey-market peptides miss their purity claims, with heavy metals and bacterial contamination in samples. Here is what to know.
Wondering about adding peptides to your GLP-1? Here is what is safe, what is not yet legal, and what your doctor needs to know.
The FDA removed 12 peptides from a restricted category in April 2026. What that means for access, safety, and your GLP-1 care.
What are peptides and how do they differ from GLP-1 medications? A plain-language guide to BPC-157, CJC-1295, ipamorelin, and more.
A plain-language refresh on the difference between a GLP-1 medication and a peptide, updated for 2026 and the arrival of non-peptide GLP-1 pills.
